Carboxypeptidases B of Anopheles gambiae as targets for a Plasmodium, falciparum transmission-blocking vaccine

Infection and Immunity

Volumn 75, Issue 4, 2007, Pages 1635-1642

  Lavazec, C ^a   Boudin, C ^b   Lacroix, R ^a   Bonnet, S ^a,c   Diop, A ^b   Thiberge, S ^a   Boisson, B ^a   Tahar, R ^a,d   Bourgouin, C ^a  

^a INSTITUT PASTEUR   (France)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (Senegal)

^c LUNAM UNIVERSITÉ   (France)

^d Organisation de Coordination pour la Lutte contre les Endemies en Afrique Centrale Cameroon   (Cameroon)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYPEPTIDASE B; CPAG1 ANTIBODY VACCINE; MALARIA VACCINE; PARASITE ANTIGEN; PROTEIN CPBAG1; TRANSMISSION BLOCKING VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOPHELES GAMBIAE; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; CPBAG1 GENE; CPBAG2 GENE; DISEASE TRANSMISSION; ENZYME ANALYSIS; GENE; GENE EXPRESSION REGULATION; MIDGUT; MOSQUITO; MOUSE; NONHUMAN; PARASITE DEVELOPMENT; PLASMODIUM FALCIPARUM; PREVALENCE; PRIORITY JOURNAL; VACCINE PRODUCTION;

ANIMALS; ANOPHELES GAMBIAE; ANTIBODIES; CARBOXYPEPTIDASE B; DISEASE MODELS, ANIMAL; FEMALE; GASTROINTESTINAL TRACT; HUMANS; MALARIA; MALARIA VACCINES; MALARIA, FALCIPARUM; MICE; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; REPRODUCTION; UP-REGULATION;

EID: 34147142425     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.00864-06     Document Type: Article

References (32)

1. Attardo, G. M., I. A. Hansen, and A. S. Raikhel. 2005. Nutritional regulation of vitellogenesis in mosquitoes: implications for anautogeny. Insect Biochem. Mol. Biol. 35:661-675.
2. Bonnet, S., G. Prevot, J. C. Jacques, C. Boudin, and C. Bourgouin. 2001. Transcripts of the malaria vector Anopheles gambiae that are differentially regulated in the midgut upon exposure to invasive stages of Plasmodium falciparum. Cell. Microbiol. 3:449-458.
3. Carter, R. 1999. Epidemiological considerations for malaria reduction by transmission blocking vaccination. Parassitologia 41:415-420.
4. Carter, R. 2001. Transmission blocking malaria vaccines. Vaccine 19:2309-2314.
5. Carter, R., K. N. Mendis, L. H. Miller, L. Molineaux, and A. Saul. 2000. Malaria transmission-blocking vaccines: how can their development be supported? Nat. Med. 6:241-244.
6. Carter, R., L. H. Miller, J. Rener, D. C. Kaushal, N. Kumar, M. Graves, C. A. Grotendorst, R. W. Gwadz, C. French, and D. Wirth. 1984. Target antigens in malaria transmission blocking immunity. Philos. Trans. R. Soc. Lond. Ser. B 307:201-213.
7. Dinglasan, R. R., I. Fields, M. Shahabuddin, A. F. Azad, and J. B. Sacci, Jr. 2003. Monoclonal antibody MG96 completely blocks Plasmodium yoelii development in Anopheles stephensi. Infect. Immun. 71:6995-7001.
8. Gupta, S., and R. M. Anderson. 1996. Predicting the effects of malaria vaccines on the population dynamics of infection and disease, p. 249-276. In S. L. Hoffman (ed.), Malaria vaccine development: a multi-immune response approach. ASM Press, Washington, DC.
9. Halloran, M. E., and C. J. Struchiner. 1992. Modeling transmission dynamics of stage-specific malaria vaccines. Parasitol. Today 8:77-85.
10. Hay, S. I., C. A. Guerra, A. J. Tatem, P. M. Atkinson, and R. W. Snow. 2005. Urbanization, malaria transmission and disease burden in Africa. Nat. Rev. Microbiol. 3:81-90.
11. Hisaeda, H., and K. Yasutomo. 2002. Development of malaria vaccines that block transmission of parasites by mosquito vectors. J. Med. Investig. 49:118-123.
12. Huff, C. G., D. F. Marchbank, and T. Shiroishi. 1958. Changes in infectious-ness of malarial gametocytes. II. Analysis of the possible causative factors. Exp. Parasitol. 7:399-417.
13. Kaslow, D. C. 1996. Transmission blocking vaccines, p. 181-227. In S. L. Hoffman (ed.), Malaria vaccine development: a multi-immune response approach. ASM Press, Washington, DC.
14. Kaslow, D. C. 1997. Transmission-blocking vaccines: uses and current status of development. Int. J. Parasitol. 27:183-189.
15. Lal, A. A., P. S. Patterson, J. B. Sacci, J. A. Vaughan, C. Paul, W. E. Collins, R. A. Wirtz, and A. F. Azad. 2001. Anti-mosquito midgut antibodies block development of Plasmodium falciparum and Plasmodium vivax in multiple species of Anopheles mosquitoes and reduce vector fecundity and survivorship. Proc. Natl. Acad. Sci. USA 98:5228-5233.
16. Lal, A. A., M. E. Schriefer, J. B. Sacci, I. F. Goldman, V. Louiswileman, W. E. Collins, and A. F. Azad. 1994. Inhibition of malaria parasite development in mosquitoes by anti-mosquito-midgut antibodies. Infect. Immun. 62:316-318.
17. Lavazec, C., S. Bonnet, I. Thiery, B. Boisson, and C. Bourgouin. 2005. cpbAg1 encodes an active carboxypeptidase B expressed in the midgut of Anopheles gambiae. Insect Mol. Biol. 14:163-174.
18. Moore, S., and W. H. Stein. 1948. Photometric ninhydrin method for use in the chromatography of amino acids. J. Biol. Chem. 176:367-388.
19. Ramasamy, M. S., and R. Ramasamy. 1990. Effect of anti-mosquito antibodies on the infectivity of the rodent malaria parasite Plasmodium berghei to Anopheles farauti. Med. Vet. Entomol. 4:161-166.
20. Rener, J., P. M. Graves, R. Carter, J. L. Williams, and T. R. Burkot. 1983. Target antigens of transmission-blocking immunity on gametes of Plasmodium falciparum. J. Exp. Med. 158:976-981.
21. Robert, V., G. le Goff, L. C. Gouagna, M. Sinden, J. Kieboom, R. Kroneman, and J. P. Verhave. 1998. Kinetics and efficiency of Plasmodium falciparum development in the midguts of Anopheles gambiae, An. funestus and An. nili. Ann. Trop. Med. Parasitol. 92:115-118.
22. Shahabuddin, M., F. J. A. Lemos, D. C. Kaslow, and M. Jacobs-Lorena. 1996. Antibody-mediated inhibition of Aedes aegypti midgut trypsins blocks sporogonic development of Plasmodium gallinaceum. Infect. Immun. 64:739-743.
23. Smith, D., and F. Ellis McKenzie. 2004. Statics and dynamics of malaria infection in Anopheles mosquitoes. Malaria J. 3:13.
24. Srikrishnaraj, K. A., R. Ramasamy, and M. S. Ramasamy. 1995. Antibodies to Anopheles midgut reduce vector competence for Plasmodium vivax malaria. Med. Vet. Entomol. 9:353-357.
25. Stowers, A., and R. Carter. 2001. Current developments in malaria transmission-blocking vaccines. Expert Opin. Biol. Ther. 1:619-628.
26. Tahar, R., C. Boudin, I. Thiery, and C. Bourgouin. 2002. Immune response of Anopheles gambiae to the early sporogonic stages of the human malaria parasite Plasmodium falciparum. EMBO J. 21:6673-6680.
27. Tchuinkam, T., B. Mulder, K. Dechering, H. Stoffels, J. P. Verhave, M. Cot, P. Carnevale, J. H. E. T. Menwissen, and V. Robert. 1993. Experimental infections of Anopheles gambiae with Plasmodium falciparum of naturally infected gametocyte carriers in Cameroon - factors influencing the infectivity to mosquitoes. Trop. Med. Parasitol. 44:271-276.
28. Tsuboi, T., M. Tachibana, O. Kaneko, and M. Torii. 2003. Transmission-blocking vaccine of vivax malaria. Parasitol. Int. 52:1-11.
29. UNICEF and World Health Organization. 2005. World malaria report. http: //rbm.who.int/wmr2005/.
30. Vaughan, J. A., B. H. Noden, and J. C. Beier. 1992. Population dynamics of Plasmodium falciparum sporogony in laboratory-infected Anopheles gambiae. J. Parasitol. 78:716-724.
31. Vermeulen, A. N., T. Ponnudurai, P. J. Beckers, J. P. Verhave, M. A. Smits, and J. H. Meuwissen. 1985. Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito. J. Exp. Med. 162:1460-1476.
32. Williamson, K. C. 2003. Pfs230: from malaria transmission-blocking vaccine candidate toward function. Parasite Immunol. 25:351-359.